Search results for "AGENTS"

showing 10 items of 7330 documents

Modulation of central corneal thickness by various riboflavin eyedrop compositions in porcine corneas

2012

Purpose To evaluate the modulatory effect of various riboflavin 0.1% and 0.2% compositions on the central corneal thickness (CCT) in fresh porcine corneas. Setting Department of Ophthalmology, Johannes Gutenberg University of Mainz, Mainz, Germany. Design Experimental study. Methods The CCT in freshly enucleated porcine globes was measured by ultrasound pachymetry before and after (if applicable) deepithelialization and every 10 minutes thereafter during 120 minutes of eyedrop application. In Groups 1 and 2 (controls), no eyedrops were applied. In Groups 3 and 4, isotonic riboflavin eyedrops were used. In Groups 5 to 9, hypotonic riboflavin eyedrops were given. In Groups 10 and 11, preparat…

medicine.medical_specialtySwineRiboflavinRiboflavinCorneaCorneal edemaCorneaOphthalmologyIsotonicAnimalsMedicineBody Weights and MeasuresUltrasonographyPhotosensitizing Agentsbusiness.industryCorneal EdemaOsmolar ConcentrationUltrasound pachymetryHydrogen-Ion ConcentrationSensory SystemsSurgeryOphthalmologyCross-Linking ReagentsOphthalmic solutionsmedicine.anatomical_structurePhotochemotherapySurgeryOphthalmic SolutionsbusinessJournal of Cataract and Refractive Surgery
researchProduct

European Society of Hypertension Working Group on Obesity: background, aims and perspectives.

2007

Clinica Medica, University ofMilano-Bicocca, Ospedale San Gerardo, Monza, Milan, ItalyCorrespondence and requests for reprints to Professor Jens Jordan, ChairmanWorking Group on Obesity, Franz Volhard Clinical Research Center, HELIOSKlinikum Berlin and Medical Faculty of the Charite´, Wiltbergstrase 50, 13125Berlin, GermanyTel: +49 30 9417 2220; fax: +49 30 9417 2265; e-mail: jens.jordan@charite.de

medicine.medical_specialtySympathetic Nervous SystemPhysiologybusiness.industryNutritional statusBlood PressureBaroreflexWeight LoSurgeryEuropeAntihypertensive AgentFamily medicineHypertensionWeight LossInternal MedicineMedicineHumansObesityCardiology and Cardiovascular MedicinebusinessAntihypertensive AgentsSocieties MedicalJournal of hypertension
researchProduct

Renal artery denervation for treating resistant hypertension: Definition of the disease, patient selection and description of the procedure

2012

Arterial hypertension is responsible for a significant burden of cardiovascular morbidity and mortality, worldwide. Although several rational and integrated pharmacological strategies are available, the control of high blood pressure still remains largely unsatisfactory. Failure to achieve effective blood pressure control in treated hypertensive patients may have a substantial impact on individual global cardiovascular risk, since it significantly increases the risk of developing hypertension-related macrovascular and microvascular complications. Arterial hypertension is arbitrarily defined as 'resistant' or 'refractory' when the recommended blood pressure goals (clinic blood pressure below…

medicine.medical_specialtySympathetic nervous systemSettore MED/09 - Medicina InternahypertensionDrug ResistanceFemoral arteryRisk AssessmentNephropathyPharmacotherapyRenal ArteryRisk Factorsmedicine.arteryInternal medicinemedicineInternal MedicineHumansArterial PressureRenal arterySympathectomyrenal artery denervationglobal cardiovascular riskantihypertensive therapyAntihypertensive AgentsSettore MED/14 - NefrologiaDenervationrefractory hypertensiontreatmentbusiness.industryPatient SelectionType 2 Diabetes Mellitusresistant hypertensionmedicine.diseaseSettore MED/11 - Malattie Dell'Apparato Cardiovascolaremedicine.anatomical_structureBlood pressureTreatment Outcomeresistant hypertension refractory hypertension renal artery denervation antihypertensive therapy global cardiovascular risk.resistant-hypertension; treatment; hypertensionCardiologyCatheter AblationHypertension treatment; Resistant-hypertension treatment; Antihypertensive Agents; Humans; Hypertension; Patient Selection; Renal Artery; Risk Assessment; Risk Factors; Sympathectomy; Treatment Outcome; Arterial Pressure; Catheter Ablation; Drug Resistance; Internal Medicine; Cardiology and Cardiovascular MedicinebusinessCardiology and Cardiovascular Medicineresistant-hypertension
researchProduct

Functional roles of the sweet taste receptor in oral and extraoral tissues

2014

International audience; Purpose of review: This review summarizes and discusses the current knowledge about the physiological roles of the sweet taste receptor in oral and extraoral tissues. Recent findings: The expression of a functional sweet taste receptor has been reported in numerous extragustatory tissues, including the gut, pancreas, bladder, brain and, more recently, bone and adipose tissues. In the gut, this receptor has been suggested to be involved in luminal glucose sensing, the release of some satiety hormones, the expression of glucose transporters, and the maintenance of glucose homeostasis. More recently, the sweet taste receptor was proposed to regulate adipogenesis and bon…

medicine.medical_specialtyTasteinsulinobesitysweetenerProtein ConformationUrinary BladderMedicine (miscellaneous)BiologyBioinformaticsReceptors G-Protein-Coupled03 medical and health sciences0302 clinical medicinestomatognathic systemInternal medicineInsulin Secretion[SDV.IDA]Life Sciences [q-bio]/Food engineeringmedicineAnimalsHumans[SPI.GPROC]Engineering Sciences [physics]/Chemical and Process EngineeringLymphocytesInsulin secretionReceptor030304 developmental biologyCARBOHYDRATES: Edited by Luc Tappy and Bettina Mittendorfer0303 health sciencesPolymorphism GeneticNutrition and Dieteticsdiabetesdigestive oral and skin physiologyfood and beveragesHeartSweetening agentsSweet tastetaste receptor functionTaste BudsGastrointestinal TractEndocrinologyAdipose TissuecarbohydrateSweetening AgentsTasteModels Animal030217 neurology & neurosurgeryInsulin metabolism
researchProduct

Combined sub-optimal doses of Rosuvastatin and Bexarotene impairs angiotensin II-induced arterial mononuclear cell adhesion through inhibition of Nox…

2015

Aim: Mononuclear cell (MC) infiltration into the arterial subendothelium is a key event in atherogenesis. Rosuvastatin (Rosu) and bexarotene (Bex) exert anti-inflammatory activity, but serious dose-related adverse effects have emerged. The need for safer and effective strategies to prevent and treat atherosclerosis led us to test the effect of combined use of both drugs on angiotensin II (Ang-II)-induced arterial MC recruitment. Results: Vehicle, Rosu (10–30 nM), Bex (0.3–1 μM), or a combination of both were administered to human umbilical arterial endothelial cells (HUAECs) 20 h before stimulation with 1 μM Ang-II (4 h). Surprisingly, a combination of Rosu (10 nM)+Bex (0.3 μM), which did n…

medicine.medical_specialtyTetrahydronaphthalenesPhysiologyPeroxisome Proliferator-Activated ReceptorsClinical BiochemistryCCL2BiologyNitric OxideBiochemistryPeripheral blood mononuclear cellCell LineInternal medicineCell AdhesionmedicineAnticarcinogenic AgentsHumansRosuvastatinInterleukin 8Rosuvastatin CalciumMolecular BiologyGeneral Environmental ScienceSistema cardiovascularBexaroteneSulfonamidesDiabetisArtèriesAngiotensin IIMembrane ProteinsNADPH OxidasesArteriesCell BiologyAngiotensin IIFluorobenzenesCXCL1Original Research CommunicationsPyrimidinesRetinoid X ReceptorsEndocrinologyNADPH Oxidase 5BexaroteneLeukocytes MononuclearGeneral Earth and Planetary SciencesSignal transductionSignal Transductionmedicine.drug
researchProduct

Efficacy and safety of open-label caplacizumab in patients with exacerbations of acquired thrombotic thrombocytopenic purpura in the HERCULES study.

2020

BACKGROUND Acquired thrombotic thrombocytopenic purpura (aTTP) is a rare, life-threatening autoimmune thrombotic microangiopathy. Caplacizumab, an anti-von Willebrand Factor Nanobody® , is effective for treating aTTP episodes and is well tolerated. OBJECTIVES AND METHODS In the phase 3 HERCULES trial (NCT02553317), patients with aTTP received double-blind caplacizumab or placebo during daily therapeutic plasma exchange (TPE) and for ≥30 days thereafter. Patients who experienced an exacerbation while on blinded study drug treatment switched to receive open-label caplacizumab plus re-initiation of daily TPE. Exacerbations were defined as recurrence of disease occurring within 30 days after ce…

medicine.medical_specialtyThrombotic microangiopathyExacerbation610 Medicine & health030204 cardiovascular system & hematologyvon Willebrand factorPlacebocaplacizumabthrombotic thrombocytopenic03 medical and health sciences0302 clinical medicineVon Willebrand factorFibrinolytic AgentsInternal medicineMedicineHumansPlatelet610 Medicine & healthAdverse effectADAMTS13 proteinAcquired Thrombotic Thrombocytopenic PurpurabiologyPlasma ExchangePurpura Thrombotic Thrombocytopenicbusiness.industryBrief ReportHematologySingle-Domain Antibodiesmedicine.diseaseTHROMBOSISpurpurabiology.proteinCaplacizumabbusinessJournal of thrombosis and haemostasis : JTH
researchProduct

Release of non-neuronal acetylcholine from the isolated human placenta is affected by antidepressants.

2007

Non-neuronal acetylcholine (ACh) is released from the human placenta into the extracellular space via organic cation transporters (OCTs). The present experiments investigated whether ACh release from epithelial cells is affected by drugs which are substrates of OCTs. The antidepressant drugs amitriptyline and doxepine were tested as both substances are not approved for pregnant women but frequently used. Release of ACh was measured in 10 min intervals over a period of 100 min. Test substances were added from t=50 min of incubation onwards. The effect was calculated by comparing the ACh release of the last three samples (t=70-100 min; B2) with that immediately before the application of the t…

medicine.medical_specialtyTime FactorsAmitriptylinePlacentaVasodilator AgentsPharmacologyIn Vitro TechniquesGeneral Biochemistry Genetics and Molecular BiologyTheophyllinePregnancyInternal medicinemedicineExtracellularHumansHypoglycemic AgentsAmitriptylineGeneral Pharmacology Toxicology and PharmaceuticsIncubationNeuronsOrganic cation transport proteinsbiologyDose-Response Relationship DrugChemistryHuman placentaGeneral MedicineAcetylcholineAntidepressive AgentsMetforminNon neuronal acetylcholineEndocrinologybiology.proteinMinoxidilAntidepressantFemaleDoxepinAcetylcholinemedicine.drugLife sciences
researchProduct

Long-Segment Early Squamous Cell Carcinoma of the Proximal Esophagus: Curative Treatment and Long-Term Follow-Up after 5-Aminolevulinic Acid (5-ALA)-…

2006

Photodynamic therapy (PDT) is an established treatment for the ablation of dysplastic Barrett's epithelium and early esophageal carcinoma, but no data have been published on curative 5-aminolevulinic acid (5-ALA)-PDT for long-segment early esophageal cancer with infiltration of the upper sphincter. We describe successful curative treatment of an unusual early long-segment squamous cell carcinoma (uT1a,N0) of the proximal esophagus (18 - 28 cm aborally), with three sessions of 5-ALA-PDT. Endoscopic and endosonographic follow-up macroscopically showed a complete remission of the tumor, proven by biopsy showing total histological ablation. After a follow-up period of 23 months, there has been …

medicine.medical_specialtyTime FactorsEsophageal NeoplasmsBiopsymedicine.medical_treatmentPhotodynamic therapyGastroenterologyDisease-Free SurvivalEndoscopy GastrointestinalInternal medicineBiopsymedicineCarcinomaHumansEsophagusPhotosensitizing Agentsmedicine.diagnostic_testbusiness.industryGastroenterologyAminolevulinic AcidMiddle AgedEsophageal cancerAblationmedicine.diseaseEndoscopymedicine.anatomical_structurePhotochemotherapyEpidermoid carcinomaCarcinoma Squamous CellbusinessFollow-Up StudiesEndoscopy
researchProduct

Effects of Refrigeration on the Bactericidal Activity of Human Milk: A Preliminary Study

2007

This study analyzed the bactericidal activity of human milk and how it is influenced by refrigerated storage. Nine samples of mature human milk were collected and divided into 3 aliquots. One was analyzed immediately, and the other 2 were refrigerated at 4 degrees C to 6 degrees C for 48 and 72 hours, respectively. All of the fresh samples exhibited bactericidal activity with an average value of 83.47% +/- 18.37%. Refrigeration for 48 hours did not cause significant modifications, whereas storage beyond 72 hours significantly lowered the degree of bacteriolysis versus fresh milk. In conclusion, human milk possesses bactericidal activity that remains stable during the first 48 hours of refri…

medicine.medical_specialtyTime FactorsMilk HumanFood Handlingbusiness.industryPostpartum PeriodGastroenterologyRefrigerationBreast milkBactericidal effectAnti-Bacterial AgentsFresh milkEndocrinologyRefrigerationInternal medicinePediatrics Perinatology and Child HealthEscherichia coliHumansMedicineFood sciencebusinessJournal of Pediatric Gastroenterology & Nutrition
researchProduct

Osteonecrosis of the jaws in patients assuming oral bisphosphonates for osteoporosis: A retrospective multi-hospital-based study of 87 Italian cases

2013

Abstract Background Bisphosphonates (BPs) are currently the chief drugs for the prevention/treatment of osteoporosis; one of their adverse effects is the osteonecrosis of the jaw (BRONJ). The primary endpoints of this multi-center cross-sectional study are: i) an observation of the clinical features of BRONJ in 87 osteoporotic, non-cancer patients; and ii) an evaluation of their demographic variables and comorbidities. Methods 87 BRONJ patients in therapy for osteoporosis with BPs from 8 participating clinical Italian centers were consecutively identified and studied. After BRONJ diagnosis and staging, comorbidities and data relating to local and drug-related risk factors for BRONJ were col…

medicine.medical_specialtyTime FactorsMultivariate analysisHeart DiseasesOsteoporosisSettore MED/50 - Scienze Tecniche Mediche ApplicateAdministration OralMandibleOsteonecrosis jawHospital based studyAdrenal Cortex HormonesRisk FactorsSettore MED/28 - Malattie OdontostomatologicheInternal medicineDiabetes MellitusInternal MedicinemedicineHumansIn patientRisk factorOral bisphopshonateAdverse effectOsteoporosis PostmenopausalAgedRetrospective StudiesAged 80 and overAlendronateBone Density Conservation AgentsDiphosphonatesbusiness.industryLiver DiseasesIncidence (epidemiology)Age FactorsMiddle Agedmedicine.diseaseSurgeryCross-Sectional StudiesItalyOral bisphopshonates; Osteonecrosis jaws; OsteoporosisHypertensionMultivariate AnalysisOsteoporosisBisphosphonate-Associated Osteonecrosis of the JawFemaleOsteonecrosis of the jawbusiness
researchProduct